These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

800 related items for PubMed ID: 16219899

  • 21. Levosimendan: a new approach for the treatment of patients with severe heart failure. A brief summary based on a clinical case.
    Morais J, Dias B, Pontes N.
    Rev Port Cardiol; 2003; 22(7-8):941-8. PubMed ID: 14587161
    [Abstract] [Full Text] [Related]

  • 22. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A.
    J Am Coll Cardiol; 2009 Jun 23; 53(25):2343-8. PubMed ID: 19539144
    [Abstract] [Full Text] [Related]

  • 23. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
    Ponschab M, Hochmair N, Ghazwinian N, Mueller T, Plöchl W.
    Eur J Anaesthesiol; 2008 Aug 23; 25(8):627-33. PubMed ID: 18405408
    [Abstract] [Full Text] [Related]

  • 24. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M, Lehtonen L.
    Curr Pharm Des; 2005 Aug 23; 11(4):435-55. PubMed ID: 15725064
    [Abstract] [Full Text] [Related]

  • 25. Levosimendan improves postresuscitation outcomes in a rat model of CPR.
    Huang L, Weil MH, Sun S, Cammarata G, Cao L, Tang W.
    J Lab Clin Med; 2005 Nov 23; 146(5):256-61. PubMed ID: 16242524
    [Abstract] [Full Text] [Related]

  • 26. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
    Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M, SURVIVE Investigators.
    JAMA; 2007 May 02; 297(17):1883-91. PubMed ID: 17473298
    [Abstract] [Full Text] [Related]

  • 27. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
    Duygu H, Ozerkan F, Zoghi M, Nalbantgil S, Yildiz A, Akilli A, Akin M, Nazli C, Ergene O.
    Int J Clin Pract; 2008 Feb 02; 62(2):228-33. PubMed ID: 17949428
    [Abstract] [Full Text] [Related]

  • 28. Levosimendan: a new option in acute cardiac failure.
    Holley AD, Ziegenfuss M.
    Emerg Med Australas; 2006 Feb 02; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract] [Full Text] [Related]

  • 29. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure.
    Kerbaul F, Rondelet B, Demester JP, Fesler P, Huez S, Naeije R, Brimioulle S.
    Crit Care Med; 2006 Nov 02; 34(11):2814-9. PubMed ID: 16971854
    [Abstract] [Full Text] [Related]

  • 30. Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study.
    Leppikangas H, Ruokonen E, Rutanen J, Kiviniemi V, Lindgren L, Kurola J.
    Ann Emerg Med; 2009 Dec 02; 54(6):811-817.e1-3. PubMed ID: 19766354
    [Abstract] [Full Text] [Related]

  • 31. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.
    Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A.
    Crit Care Med; 2012 Feb 02; 40(2):634-46. PubMed ID: 21963578
    [Abstract] [Full Text] [Related]

  • 32. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT.
    Am J Cardiol; 2006 Dec 15; 98(12):1641-5. PubMed ID: 17145226
    [Abstract] [Full Text] [Related]

  • 33. Evidence-based use of levosimendan in different clinical settings.
    De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M.
    Eur Heart J; 2006 Aug 15; 27(16):1908-20. PubMed ID: 16682381
    [Abstract] [Full Text] [Related]

  • 34. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
    de Lissovoy G, Fraeman K, Salon J, Chay Woodward T, Sterz R.
    J Med Econ; 2008 Aug 15; 11(3):415-29. PubMed ID: 19450096
    [Abstract] [Full Text] [Related]

  • 35. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
    Cavana M, Pignataro C, Fraticelli A, Mebazaa A.
    Ital Heart J; 2003 May 15; 4 Suppl 2():61S-64S. PubMed ID: 14635372
    [Abstract] [Full Text] [Related]

  • 36. Safety of levosimendan and other calcium sensitizers.
    Lehtonen L, Mills-Owens P, Akkila J.
    J Cardiovasc Pharmacol; 1995 May 15; 26 Suppl 1():S70-6. PubMed ID: 8907134
    [Abstract] [Full Text] [Related]

  • 37. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG, Kanakakis JV, Nanas S, Bonios M, Kaldara E, Katsaros F, Pantsios C, Nanas JN.
    J Cardiovasc Pharmacol; 2009 Feb 15; 53(2):157-61. PubMed ID: 19188832
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.